 |
1kits（10Vials）
| Quantity: | |
|---|---|
▎Vesugen Research
Molecular Background
Vesugen is a trade designation used in the published literature for the synthetic tripeptide Lys-Glu-Asp (KED). PubChem lists lysyl-glutamyl-aspartic acid under CID 87571363, with the sequence KED, molecular formula C15H26N4O8, and a molecular weight of approximately 390.39 g/mol. Published studies have examined KED in cell-culture, animal, and molecular-modeling systems; the findings remain specific to the experimental conditions in which they were generated.[9]
Research Progress
V. Kh. Khavinson and colleagues examined Vesugen and the D-7 peptide in tissue-specific cell cultures obtained from young and old animals and in dissociated vascular endothelial cell cultures. The authors reported increased expression of the proliferation-associated protein Ki-67 after peptide exposure. Molecular-docking analysis was also used to model possible interactions of Vesugen and D-7 with the promoter region of the MKI67 gene. In the computational model, both peptides contacted a CATC sequence within the reported core promoter region. Because this component of the study was based on molecular docking, it supports a proposed interaction model rather than direct experimental demonstration of peptide binding to genomic DNA in cells.[2]
Vladimir Khavinson and colleagues investigated KED and EDR peptides in a 5xFAD mouse model and in related neuronal experiments. KED was administered intraperitoneally to 5xFAD mice from 2 to 4 months of age under the study protocol. The authors reported that KED tended to increase hippocampal neuroplasticity and that KED and EDR were associated with preservation of dendritic-spine measurements in the experimental model. Molecular modeling and peptide-DNA docking were used to explore possible sequence-dependent interactions as a proposed mechanism. These observations were generated in a genetically modified mouse model and computational systems and do not establish effects in humans.[3]
Fig1. Hippocampal long-term-potentiation measurements reported in wild-type and 5xFAD mice exposed to physiological solution, EDR, or KED in the cited study.[3]
The source figure shows the time course of the fEPSP slope before and after LTP induction and the relative fEPSP slope used to estimate plasticity. Group definitions, statistical analysis, and complete experimental conditions are reported in the original publication.[3]
N. I. Chalisova and colleagues studied Lys-Glu-Asp in organotypic cultures of neuroimmunoendocrine system tissues and in a honeybee associative-learning model. In the tissue-culture experiments, the authors reported changes in proliferation- and apoptosis-related markers, including higher Ki-67 and lower p53 measurements in pineal-gland cultures, together with changes in CD5 and CD68 expression. The magnitude of some responses differed between cultures derived from younger and older animals. The publication also reported changes in associative-learning measurements in honeybees. These findings describe organotypic culture and invertebrate behavioral models rather than clinical outcomes.[1]
N. S. Linkova and colleagues examined the cellular composition of pineal lymphoid tissue in organotypic culture and compared several short peptides. The authors reported that Vilon and Epithalon influenced differentiation toward selected lymphocyte populations, whereas the tripeptide Vesugen did not alter the differentiation capacity of pineal immune cells but was associated with increased proliferative potential. The study therefore reported a proliferation-related response for Vesugen without demonstrating the same differentiation effects observed with the comparator peptides.[4]
N. A. Kraskovskaya and colleagues used primary mouse hippocampal neurons exposed to amyloid-related synaptotoxic conditions as an in vitro model. At the concentration reported in the publication, EDR was associated with a 71% increase in mushroom-spine number, while KED was associated with an approximately 20% increase compared with the model condition. These measurements were obtained in cultured mouse neurons and should remain limited to the in vitro experimental system described by the authors.[5]
L. S. Kozina and colleagues evaluated the short regulatory peptides Pinealon, Vesugen, Vilon, and Epitalon in several in vitro model systems. The authors reported that the peptides did not demonstrate direct antioxidant activity in the assays used but altered lipid-peroxidation measurements in human lipoprotein preparations and increased erythrocyte-membrane stability against osmotic hemolysis. They also reported changes in intracellular reactive-oxygen-species measurements and neuronal-cell viability, with peptide-specific differences across the tested systems. The work was conducted in vitro and did not establish in vivo pharmacology or clinical effects.[6]
Elena Sakhenberg and colleagues used an in vitro transdifferentiation system combining microRNAs, transcription factors, and small molecules to generate induced neuronal cells from fetal mesenchymal stem cells. KED, EDR, and AEDG were evaluated during the later stage of the process. The authors reported that AEDG and KED were associated with a 15% decrease in p21 expression and a 1.51- to 2.4-fold decrease in beta-galactosidase activity under the study conditions. The peptides did not significantly change TUj-1 or LaminB1 expression. These findings were obtained in an engineered in vitro differentiation model.[7]
Fig2. Cell morphology after exposure to short peptides during the in vitro neuronal-transdifferentiation experiment.[7]
The source figure shows representative phase-contrast microscopy images of induced neuronal cells in the control condition and after AEDG, EDR, or KED exposure. Complete culture conditions and analytical methods are reported in the original publication.[7]
Sergio Caputi and colleagues investigated AED, KED, KE, AEDG, and a mixture of the four peptides in human periodontal ligament stem cells cultured under basal and neuroinductive conditions. Using immunofluorescence and Western blot analysis, the authors reported higher GAP43 and Nestin expression in selected KED and peptide-mixture conditions. MTT measurements also showed peptide- and time-dependent differences in cell proliferation. These results were obtained in cultured human stem cells and represent in vitro differentiation-related findings rather than evidence of neurological effects in humans.[8]
Fig3. MTT proliferation measurements reported in human periodontal ligament stem cells exposed to AEDG, KE, AED, KED, or the peptide mixture.[8]
The source figure compares optical-density measurements at 24, 48, and 72 hours and after 1 week of culture. Statistical comparisons and complete culture conditions are reported in the original publication.[8]
Research Limitations
The evidence summarized above is predominantly based on organotypic cultures, primary neuronal cultures, stem-cell systems, animal models, and molecular-docking analyses. These approaches address different experimental questions and are not directly interchangeable. In particular, molecular docking of KED with the MKI67 promoter is a computational model and does not by itself demonstrate direct genomic binding or target engagement in living cells.[2] The cited studies also do not establish the pharmacokinetic profile, systemic bioavailability, long-term safety, or clinical efficacy of Vesugen/KED in humans.
Another limitation is the concentration of the evidence within overlapping research groups and the limited independent replication of the proposed peptide-bioregulator mechanisms. KED also produced different responses across cell types: for example, Vesugen increased proliferative potential without altering immune-cell differentiation in pineal cultures, while other studies reported changes in neuronal or stem-cell markers.[4,7,8] Interpretation should therefore remain tied to the exact peptide identity, model, concentration, and endpoint reported in each publication.
COCER Peptides presents Vesugen (KED) solely for laboratory research and analytical use. It is not intended for human or veterinary use. This material is not represented as an FDA-approved drug product, medicine, dietary supplement, medical device, or veterinary product. The research described above summarizes findings reported in third-party publications and is not a statement of clinical efficacy, safety, diagnosis, treatment, prevention, or an instruction for use.
